Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

Immunotherapy for Lung Cancer

Drugs that empower the immune system to recognize and fight cancer have proven to be a very effective way to treat patients with lung cancer. MSK has been a pioneer in developing this approach, known as immunotherapy.   

In 2015, the FDA approved two new immunotherapy drugs, nivolumab (Opdivo®) and pembrolizumab (Keytruda®), for the treatment of non-small cell lung cancer that has stopped responding to standard chemotherapy — in other words, as second-line therapy.

Both of these medications block a protein called PD-1 found on immune cells. PD-1 acts like a brake on the immune system, tamping down immune responses. Nivolumab and pembrolizumab release this brake, allowing the immune system to mount a stronger attack against cancer.

Lung Cancer Clinical Trials & Research
Patients can access new lung cancer treatments that might not be available elsewhere through our program of clinical trials.
Learn more

In addition to these FDA-approved drugs, several experimental immunotherapy drugs are being tested in clinical trials for patients with lung cancer.

Clinical trials are testing immunotherapy drugs in all settings: before and after surgery for early stage lung cancers, as first-line therapy in patients with advanced lung cancers, and in patients who have previously received chemotherapy. There are trials available for multiple forms of lung cancer, including non-small cell lung cancer and small cell lung cancer. MSK patients may be eligible to enroll in these and other clinical trials of promising new lung cancer treatments.